Recently, the Hague Division of the Unified Patent Court (UPC) held hearings on two applications for provisional measures (PM) filed by Abbott against blood glucose meter products manufactured by Sinocare and the Menarini Group. (Case numbers: ACT_30994/2025 and ACT_30994/2025)

Abbott, a global healthcare company founded in 1888 and headquartered in the United States, operates across pharmaceuticals, diagnostics, medical devices, and nutrition products. Sinocare, established in 2002 in Changsha, Hunan, specializes in developing, manufacturing, and marketing rapid diagnostic products for chronic diseases using biosensor technology. Menarini Group, a multinational pharmaceutical company founded in 1897 and headquartered in Florence, Italy, distributes Sannuo Biotech's GlucoMen iCan system in Europe through its medical devices division.

Abbott alleges that the two defendants infringed upon its two patents (EP 3 988 471 and EP 4 344 633) and seeks an injunction against the sale of the relevant products within the jurisdiction of the Unified Patent Court.

The EP 471 patent pertains to medical device display technology. Previously, Abbott asserted this patent against Dexcom in the Paris Regional Chamber, while Dexcom challenged its validity. The European Patent Office (EPO) Opposition Division upheld the validity of the amended EP 471 patent, with neither party appealing. Ultimately, the parties reached a settlement in January 2025 resolving their global patent dispute. The EP 633 patent originates from another Abbott patent family, primarily protecting analyte sensor assemblies.

Additionally, Abbott filed separate patent lawsuits against Silicon-based Biosciences in 2024 at the Hague and Düsseldorf District Courts (though involving different patents).